Verma S, et al. - In the phase 3 MONALEESA-2 study, researchers assessed the impact of first-line ribociclib plus letrozole on patient-reported outcomes (PROs) in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. They used the European Organisation for Research and Treatment of Cancer core quality-of-life and breast cancer-specific questionnaires to assess the PROs in patients randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. They found a consistently maintained health-related quality of life (HRQoL) from baseline in those treated with ribociclib plus letrozole. Compared with the placebo/letrozole arm, these patients had similar HRQoL. In this patient population, ribociclib plus letrozole offered improved clinical efficacy, a manageable safety profile, and was shown to yield a benefit.